Alembic Pharmaceuticals Ltd

Alembic Pharma | 533573

Market Closed

₹948.85

+₹0.00 (+4.96%)

As on 18/11/25, 11:53 PM

Market Cap17,770.29 CR

Current Price₹948.85

High / Low₹1,123.95 / 725.2

PE Ratio31.31

Book Value₹264.1

Dividend Yield1.18%

ROCE13.08%

ROE9.96%

Face Value₹2.00

Current Vol.2,73,066

Average Vol.12,76,53,456

ISININE901L01018

PB Ratio3.52

Debt to Equity0.18

Net Profit Margin8.72

Operating Margin15.95

Stock cgart

Stock Performance

₹2,480₹2,490

₹2,500

Previous CloseToday's Open

₹1,800₹3,000

₹2,500

52W Low52W High

₹2,480Today's Open

₹2,490Previous Close

12,00,000Volume

₹1,80052W Low

₹3,00052W High

Ratios

No data available

About Company

Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world
The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA
The company is one of the leaders in branded generics in India
Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited
The company is engaged in pharmaceuticals business
As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010
In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement
The shareholding of Alembic Ltd in the company reduced from 100% to 29
Thus, the company became an associate of Alembic Ltd
In September 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

;

Technical Indicators

RSI57.38

SMA 20920.98

SMA 50929.74

SMA 100955.94

SMA 200924.93

SMA 10925.13

MACD_12_26_Days-1.27

EMA10Day922.62

EMA20Day922.41

EMA50Day930.54

MACD_12_26_9_Days2.02

EMA100Day940.94

EMA200Day950.04

Pivot Points

Volume Analysis

Growth Rate

Revenue Growth7.12%

ROE11.63%

EBITDA Margin15.95%

All figures in ₹ Crores

Indicators	2025	2024	2023	2022	2021
Revenue	6,672.08	6,228.63	5,652.62	5,305.79	5,393.13
Interest	78.77	56.19	50.17	17.73	16.02
Expenses	5,663.84	5,296.24	4,975.17	4,431.63	3,912.84
Financing Profit	1,051.66	960.69	680.19	929.90	1,567.58
Financing Margin %	16%	15%	12%	18%	29%
Other Income	43.42	28.30	2.74	55.74	87.29
Depreciation	278.58	272.67	275.43	286.78	183.48
Profit before tax	707.18	631.83	354.59	625.39	1,368.08
Tax %	18%	3%	4%	17%	19%
Net Profit	582.01	615.82	341.99	520.94	1,114.76
EPS in Rs	29.68	31.33	17.40	26.50	59.18

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

Deal	Date	Type	Quantity	Price	Traded %
ISHARES CORE EMERGING MARKETS MAURITIUS CO	03 Oct ‘22	Sell	1,78,908	₹604.65	167.92%
ISHARES CORE MSCI EMERGING MARKETS ETF	03 Oct ‘22	Purchase	1,78,908	₹604.65	167.92%
ISHARES INDIA SC MAURITIUS COMPANY	03 Oct ‘22	Sell	25,151	₹604.65	23.61%
ISHARES MSCI INDIA SMALL-CAP ETF	03 Oct ‘22	Purchase	25,151	₹604.65	23.61%

News

17 Nov 2025 12:00 am

Alembic Pharma gains after generic gets USFDA nod

15 Nov 2025 12:00 am

Alembic Pharma receives USFDA approval for Diltiazem hydrochloride tablets

15 Nov 2025 12:00 am

Alembic Pharma gets US FDA approval for angina treatment drug Diltiazem

13 Nov 2025 12:00 am

Alembic Pharma receives USFDA nod for Dexlansoprazole Delayed-Release Capsules

Record Date

Corporate Action

Information

Announcement Day

05 Aug 2025

AGM

11 Jun 2025

29 Jul 2025

Final Dividend (₹11)

Please find attached herewith the Financial Results for the quarter and Financial Year ended 31st March, 2025 Recommended a dividend of Rs. 11/- (550%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting. This is to inform that the Company has fixed the Record Date of 29th July, 2025 for determining the entitlement of Members of the Company to receive dividend for the Financial Year ended 31st March, 2025. (As Per BSE Announcement Dated on :11.06.2025)

06 May 2025

22 Jul 2024

AGM

21 Jun 2024

15 Jul 2024

Final Dividend (₹11)

The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today Approved the Audited Financial Results for the quarter and financial year ended 31st March, 2024, and Recommended a dividend of Rs. 11/- (550%) per Equity Share

09 May 2024

04 Aug 2023

AGM

05 Jun 2023

28 Jul 2023

Final Dividend (₹8)

The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia Approved the Audited Financial Results for the quarter and financial year ended 31st March, 2023. and Recommended a dividend of Rs. 8/- (400%) per Equity Share. The Company has fixed Friday, 28th July, 2023 as the record date for determining the entitlement of Members to final dividend for the financial year ended 31st March, 2023. (As Per BSE Announcement Dated on 21.06.2023)

05 May 2023

11 Nov 2022

AGM

19 Sept 2022

18 Aug 2022

Interim Dividend (₹10)

Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 02, 2022, inter alia, has recommended a dividend of Rs. 10/- (500%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting. With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved: 1) Unaudited Financial Results for the quarter ended 30th June, 2022. 2) Re-classification of the dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22. Please note that the said interim dividend will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Thursday, 18th August, 2022. No further final dividend for the financial year 2021-22 shall be declared. The time of commencement of the Board Meeting was 12:30 p.m. and the time of conclusion was 3:30 p.m. We request you to kindly take the same on record. (As Per BSE Announcement Dated on 04.08.2022)

02 May 2022

14 Jun 2022

EGM

10 May 2022

27 Jul 2021

AGM

28 May 2021

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
913	17,954	28	3	19	0	8.72%
1,760	4,22,211	37	5	30	0	20.88%
6,475	1,71,898	69	11	59	0	23.41%
3,793	1,28,372	59	15	43	1	16.60%
1,515	1,22,349	22	4	19	0	19.21%
1,244	1,03,789	18	3	14	0	17.54%
2,047	93,506	22	5	17	0	14.56%
928	93,404	19	4	15	0	19.86%
2,224	91,800	53	6	35	0	14.39%
1,240	72,630	21	2	14	0	10.98%

Showing 10 of 124 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in less than 10 mins*

By proceeding, you agree to all T&C *

Top Gainers

Top Losers

Frequently Asked Questions

What is Share Price of Alembic Pharmaceuticals Ltd?

The current share price of Alembic Pharmaceuticals Ltd (Alembic Pharma) is ₹948.85. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Alembic Pharmaceuticals Ltd?

The Price-to-Earnings (P/E) ratio of Alembic Pharmaceuticals Ltd is 948.85. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd has a 52-week high of ₹1123.95 and a 52-week low of ₹725.20. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd offers a dividend yield of 1.22%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Alembic Pharmaceuticals Ltd?

The Earnings Per Share (EPS) of Alembic Pharmaceuticals Ltd is ₹32.27. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd has a Return on Equity (ROE) of 9.96%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds.